280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial. - Eto, M.; Motzer, R.J.; Choueiri, T.K.; Haanen, J.B.A.G.; Oya, M.; Uemura, H.; Venugopal, B.; Rini, B.I.; Miyake, H.; Albiges, L.; Schmidinger, M.; Tomita, Y.; et al. (Annals of Oncology, 2024)